PL3233857T3 - Stałe postacie skondensowanych heteroaromatycznych pirolidynonów - Google Patents

Stałe postacie skondensowanych heteroaromatycznych pirolidynonów

Info

Publication number
PL3233857T3
PL3233857T3 PL15831150T PL15831150T PL3233857T3 PL 3233857 T3 PL3233857 T3 PL 3233857T3 PL 15831150 T PL15831150 T PL 15831150T PL 15831150 T PL15831150 T PL 15831150T PL 3233857 T3 PL3233857 T3 PL 3233857T3
Authority
PL
Poland
Prior art keywords
solid state
state forms
fused heteroaromatic
pyrrolidinones
heteroaromatic pyrrolidinones
Prior art date
Application number
PL15831150T
Other languages
English (en)
Polish (pl)
Inventor
Rongliang Chen
Tomonori ICHIBAKASE
Chunrong Ma
Christopher Matthews
Hajime MOTOYOSHI
Colin O'bryan
Kentaro YAJI
Naoki Yoshikawa
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55299676&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3233857(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of PL3233857T3 publication Critical patent/PL3233857T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
PL15831150T 2014-12-18 2015-12-17 Stałe postacie skondensowanych heteroaromatycznych pirolidynonów PL3233857T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462093564P 2014-12-18 2014-12-18
US201562115223P 2015-02-12 2015-02-12
US201562180222P 2015-06-16 2015-06-16
PCT/IB2015/002489 WO2016097862A2 (en) 2014-12-18 2015-12-17 Solid state forms of fused heteroaromatic pyrrolidinones
EP15831150.6A EP3233857B1 (en) 2014-12-18 2015-12-17 Solid state forms of fused heteroaromatic pyrrolidinones

Publications (1)

Publication Number Publication Date
PL3233857T3 true PL3233857T3 (pl) 2020-07-27

Family

ID=55299676

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15831150T PL3233857T3 (pl) 2014-12-18 2015-12-17 Stałe postacie skondensowanych heteroaromatycznych pirolidynonów

Country Status (29)

Country Link
US (3) US10676473B2 (OSRAM)
EP (2) EP3233857B1 (OSRAM)
JP (3) JP6778195B2 (OSRAM)
KR (1) KR102037502B1 (OSRAM)
CN (1) CN107108609B (OSRAM)
AU (1) AU2015365580B2 (OSRAM)
BR (1) BR112017013149B1 (OSRAM)
CA (1) CA2970864C (OSRAM)
CL (1) CL2017001561A1 (OSRAM)
CO (1) CO2017005910A2 (OSRAM)
CR (1) CR20170249A (OSRAM)
DK (1) DK3233857T3 (OSRAM)
DO (1) DOP2017000130A (OSRAM)
EA (1) EA032291B1 (OSRAM)
EC (1) ECSP17038100A (OSRAM)
ES (1) ES2788454T3 (OSRAM)
GE (1) GEP20197050B (OSRAM)
IL (1) IL252941B (OSRAM)
MX (1) MX373586B (OSRAM)
MY (1) MY199935A (OSRAM)
NZ (1) NZ732371A (OSRAM)
PE (1) PE20171179A1 (OSRAM)
PH (1) PH12017501123A1 (OSRAM)
PL (1) PL3233857T3 (OSRAM)
SG (1) SG11201701911QA (OSRAM)
TN (1) TN2017000080A1 (OSRAM)
UA (1) UA120632C2 (OSRAM)
WO (1) WO2016097862A2 (OSRAM)
ZA (1) ZA201701800B (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3233857T3 (pl) * 2014-12-18 2020-07-27 Takeda Pharmaceutical Company Limited Stałe postacie skondensowanych heteroaromatycznych pirolidynonów
CA3030630A1 (en) * 2016-07-13 2018-01-18 Takeda Pharmaceutical Company Limited Combination of spleen tyrosine kinase inhibitors and other therapeutic agents
JP2020537678A (ja) 2017-10-19 2020-12-24 バイエル・アニマル・ヘルス・ゲーエムベーハー 動物における疾患の治療および予防のための縮合ヘテロ芳香族ピロリドンの使用
WO2019088039A1 (en) 2017-10-30 2019-05-09 Takeda Pharmaceutical Company Limited Treatment of acute myeloid leukemia
ES2971892T3 (es) * 2018-12-14 2024-06-10 Chia Tai Tianqing Pharmaceutical Group Co Ltd Formas cristalinas del inhibidor de Syk sal hidrocloruro de 5-fluoro-1-metil-3-[[5-[4-(3-oxetanil)-1-piperazinil]-2-piridinil]amino]-6-(1H-pirazol-3-il)-2(1H)-quinolinona (1:1)
CN113453680A (zh) 2019-02-07 2021-09-28 詹森生物科技公司 二氢乳清酸脱氢酶抑制剂
TW202104207A (zh) 2019-04-17 2021-02-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
WO2021070132A1 (en) 2019-10-10 2021-04-15 Janssen Biotech, Inc. Bi-aryl dihydroorotate dehydrogenase inhibitors
AU2020404305A1 (en) 2019-12-19 2022-08-04 Janssen Pharmaceutica Nv Substituted straight chain spiro derivatives
WO2022074534A1 (en) 2020-10-05 2022-04-14 Janssen Biotech, Inc. Combinations of dihydroorotate dehydrogenase inhibitors and hypomethylating agents
WO2022127753A1 (zh) * 2020-12-18 2022-06-23 山东轩竹医药科技有限公司 稠环类AhR抑制剂
JP2024518497A (ja) 2021-05-11 2024-05-01 ヤンセン ファーマシューティカ エヌ.ベー. 併用療法
KR20240006638A (ko) 2021-05-11 2024-01-15 얀센 파마슈티카 엔브이 조합 요법
CN120322230A (zh) 2022-11-30 2025-07-15 詹森药业有限公司 包含多发性内分泌癌蛋白-mll抑制剂和至少一种其他治疗剂的组合
WO2024114666A1 (en) 2022-11-30 2024-06-06 Janssen Pharmaceutica Nv Combinations comprising a menin-mll inhibitor and a bcl-2 inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1960372B1 (en) * 2005-12-15 2015-12-09 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
US8440689B2 (en) 2009-12-23 2013-05-14 Takeda Pharmaceutical Company Limited Fused heteroaromatic pyrrolidinones
EP2723739B1 (en) 2011-06-22 2016-08-24 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
TW201625263A (zh) * 2014-09-24 2016-07-16 千禧製藥公司 利用PI3Kα抑制劑與紫杉烷之組合治療
PL3233857T3 (pl) * 2014-12-18 2020-07-27 Takeda Pharmaceutical Company Limited Stałe postacie skondensowanych heteroaromatycznych pirolidynonów

Also Published As

Publication number Publication date
JP2017537969A (ja) 2017-12-21
ES2788454T3 (es) 2020-10-21
PE20171179A1 (es) 2017-08-22
MY199935A (en) 2023-11-29
CA2970864C (en) 2020-04-14
HK1243406A1 (zh) 2018-07-13
CN107108609A (zh) 2017-08-29
BR112017013149A2 (pt) 2018-04-10
TN2017000080A1 (en) 2018-07-04
MX2017007162A (es) 2017-08-28
JP2020143081A (ja) 2020-09-10
PH12017501123A1 (en) 2017-11-27
EP3233857A2 (en) 2017-10-25
ECSP17038100A (es) 2017-12-01
EA032291B1 (ru) 2019-05-31
JP6974534B2 (ja) 2021-12-01
CL2017001561A1 (es) 2018-01-12
JP2022017477A (ja) 2022-01-25
US20230348461A1 (en) 2023-11-02
IL252941A0 (en) 2017-08-31
GEP20197050B (en) 2019-12-10
AU2015365580A1 (en) 2017-07-06
KR20170095374A (ko) 2017-08-22
US11352355B2 (en) 2022-06-07
CA2970864A1 (en) 2016-06-23
NZ732371A (en) 2023-04-28
CN107108609B (zh) 2020-02-18
US10676473B2 (en) 2020-06-09
CO2017005910A2 (es) 2017-10-20
BR112017013149B1 (pt) 2022-10-11
MX373586B (es) 2020-05-05
IL252941B (en) 2020-11-30
ZA201701800B (en) 2020-05-27
EP3677582B1 (en) 2023-01-25
EP3233857B1 (en) 2020-03-11
UA120632C2 (uk) 2020-01-10
SG11201701911QA (en) 2017-04-27
WO2016097862A2 (en) 2016-06-23
KR102037502B1 (ko) 2019-10-28
CR20170249A (es) 2017-09-25
EA201791369A1 (ru) 2017-10-31
DOP2017000130A (es) 2017-07-15
JP6778195B2 (ja) 2020-10-28
WO2016097862A3 (en) 2016-08-11
DK3233857T3 (da) 2020-04-27
US20160176869A1 (en) 2016-06-23
AU2015365580B2 (en) 2020-04-02
US20200339573A1 (en) 2020-10-29
EP3677582A1 (en) 2020-07-08

Similar Documents

Publication Publication Date Title
IL252941A0 (en) Solid state forms of conjugated heteroaromatic pyrrolidinones
IL258180B (en) Heterocyclic compounds and their uses
IL246838A0 (en) A fused heterocyclic compound
IL248312A0 (en) suspension element
SG11201605417QA (en) Heterocyclic compounds
IL257026A (en) Solid state forms of eluxadoline
EP3133075A4 (en) Fused heterocyclic compound
HU4602U (en) Set of saggar assembly
SI3524234T1 (sl) Trdne oblike sofosbuvira
IL265628A (en) Solid state forms of valbenazine
GB201411526D0 (en) Powder
IL246979A0 (en) Crystalline forms of sofosbuvir
ZA201606077B (en) Pyrazines modulators of gpr6
ZA201706282B (en) Solid forms of menaquinols
ZA201606598B (en) Novel fused imidazobenzothiazole compounds
HU4603U (en) Set of saggar assembly
IL246569A0 (en) Solid forms of tenofovir
GB201416351D0 (en) Heterocyclic derivatives
IL254666A0 (en) Crystalline forms of Aldecalcitol
IL249332A0 (en) Crystalline forms of sofosbuvir
GB2557903B (en) Suspension element
GB201421941D0 (en) Suspension bridges
GB201421938D0 (en) Suspension bridges
GB201421944D0 (en) Suspension bridges
GB201418230D0 (en) Construction of surfaces